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The past decade has brought enormous advances in the way
we manage breast cancer patients with systemic therapies.
An explosion in our understanding of the molecular patho-
genesis of breast cancer, a harnessing of powerful new
diagnostic technologies, and the culmination of a series of
pivotal randomized trials of cytotoxic and novel targeted
therapies have yielded significant improvements in outcomes
for patients with both early and advanced disease. A series of
review articles published in Breast Cancer Research written
by leading clinical researchers explores these advances in
different areas of breast cancer management.
Miles [1] discusses new advances in the management of
metastatic breast cancer focusing particularly on human
epidermal growth factor receptor (HER)-negative disease. His
review addresses pivotal trials of cytotoxic therapy and
highlights optimal management in 2009. In addition, it focuses
on the role played by targeted agents, and particularly anti-
angiogenic agents, highlighting new data with agents such as
bevacizumab. New approaches to the management of ‘triple
negative’ breast cancer are also discussed.
Advances in the management of patients with HER2-positive
metastatic breast cancer are reviewed by Esteva and
colleagues [2]. Optimal use of currently available targeted
agents such as trastuzumab and lapatanib are discussed,
including the use of both in clinical scenarios such as relapse
after adjuvant trastuzumab or progression following first-line
use of trastuzumab in the metastatic setting. The potential
role of newer agents targeting the HER family are also high-
lighted, as is the case for the use of combined targeted agents.
Key issues in the use of adjuvant systemic therapy for early
breast cancer are reviewed by Martín and López-Tarruella [3].
Current ‘gold standard’ options for the use of adjuvant
chemotherapy are discussed within the setting of node-
positive and node-negative disease. Issues such as which
patients should receive taxane-based chemotherapy and the
optimal schedule for such regimens are covered. Clinical
trials of novel targeted therapies are also discussed.
The increasing use of neoadjuvant systemic therapy is
highlighted by Untch and von Minckwitz [4]. Pivotal trials in
this area are reviewed, and the use of clinical and biological
surrogate markers of long-term outcome is discussed.
Finally, Di Leo and colleagues [5] discuss the evidence base
behind some of the new molecular prognostic and predictive
profile technologies. They review the concept of using
biomarkers to predict outcome and the place of tests such as
Oncotype DX (Genomic Health, Redwood, CA, USA) and
MammaPrint (Agendia, Huntington Beach, CA, USA). What
do they add over existing expertise and in which areas should
they be used in everyday practice, if at all? They also discuss
ongoing clinical trials using these technologies, such as the
TAILORx (Trial for Assigning IndividuaLized Options for
Treatment) and MINDACT (Microarray In Node-negative
Disease may Avoid ChemoTherapy) trials.
In summary these reviews provide a snapshot of current
state-of-the-art medical practice in the use of systemic
cytotoxic and targeted therapy for breast cancer manage-
ment. If the past decade has helped to crystallize incremental
gains in outcome for patients with early and metastatic
disease, this decade promises further advance by using the
molecular advances described above to help identify which
groups of patients may gain from particular types of therapy.
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